Overview

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Antibodies, Monoclonal
Ipilimumab
Sunitinib
Tremelimumab